The cost of employer stop-loss coverage is on a steep upward trajectory, driven by a confluence of forces reshaping the self-funded health plan landscape. Over the past three years, premiums for both specific and aggregate stop-loss have increased at a pace not seen in over a decade. While still a critical risk management tool, stop-loss is evolving from a relatively stable backstop into a dynamic, often volatile, piece of the benefits financing puzzle. Employers and their advisors need to understand not just the numbers, but the underlying medical, economic, and market trends fueling these increases to plan effectively.
The Rise of Self-Funding and Its Impact on Stop-Loss
The surge in stop-loss costs cannot be separated from the sustained migration toward self-funding. As traditional fully insured premiums remain unpredictable, more mid-size and even smaller employers are adopting level-funded and self-funded arrangements. This expansion of the risk pool has introduced a larger volume of smaller groups, which often have less predictable claims experience and thinner risk margins. Carriers are responding by tightening underwriting standards, raising attachment points, and increasing premium rates to protect against the greater frequency and severity of claims in this growing segment.
Key Drivers of Stop-Loss Cost Increases
Several powerful cost accelerators are converging to push stop-loss rates higher. These are not temporary blips but structural shifts that will likely persist:
- High-cost specialty drugs: The explosion of gene therapies, cell therapies, and novel biologics, often carrying price tags of $2 million to $4 million per treatment, is directly hitting specific stop-loss layers. Hemgenix, a hemophilia B gene therapy, lists at $3.5 million, and Orchard Therapeutics' Lenmeldy lists at $4.25 million. A single claim of that size can wipe out an employer's margin, making carriers far more cautious.
- Medical inflation and provider consolidation: Unit costs are increasing rapidly, fueled by hospital system mergers and growing market power. This inflates the size of catastrophic claims and raises the baseline for aggregate attachment points.
- Increased utilization: Mental health and substance use disorder claims are up, as are bariatric surgeries and advanced imaging, and these volumes are driving higher cost trends across the board.
- Aging workforce and chronic disease prevalence: Population health risk is not improving, leading to a steady increase in million-dollar-plus claimants. Sun Life reported a 29% increase in claims of $1 million or more per million covered employees in 2024 and a 47% increase in claims totaling $3 million or more.
Specific vs. Aggregate Stop-Loss: Diverging Trends
While both types of coverage are seeing increases, the dynamics differ. Specific stop-loss (which protects against individual high-dollar claims) is experiencing the most intense upward pressure due to the impact of multi-million dollar drug and transplant claims. The 2026 Aegis Risk Medical Stop-Loss Premium Survey measured specific premium increases of 13.6% to 15.9% depending on deductible, and several large direct underwriters reported increases in the low 20% range on their own books. Renewal rates still vary widely by group size, industry, and prior experience. Carriers are also raising specific deductibles (attachment points) to maintain viable rate structures, effectively shifting more initial risk back to the employer.
Aggregate stop-loss (which caps total claims liability) is becoming more expensive and harder to obtain for groups with inconsistent demographics. Underwriters are increasingly using laser-focused underwriting, excluding or sub-limiting known high-risk individuals from aggregate coverage, and requiring more detailed historic claims data. Aggregate premiums are also climbing, and underwriters are tightening margins at renewal; the median monthly aggregate premium per covered employee was $7.93 in the 2026 Aegis Risk survey.
GLP-1 Drugs Add a New Layer of Aggregate Pressure
Gene and cell therapies are one-time, multi-million dollar events that land in the specific layer. GLP-1 drugs are different: Wegovy, Zepbound, and similar medications are recurring, high-cost maintenance therapies that inflate claims across an entire covered population. GLP-1s now account for roughly 14% of U.S. prescription drug spending, and WTW's Rx Collaborative measured GLP-1 costs climbing from $1.50 per member per month in 2019 to $27.23 in the first quarter of 2025. Coverage has spread quickly: KFF found that 19% of firms with 200 or more workers and 43% of firms with 5,000 or more covered GLP-1 drugs for weight loss in 2025. The Employee Benefit Research Institute has estimated that expanding GLP-1 coverage can raise employer health premiums by 6% to nearly 14% a year depending on how broadly the drugs are covered.
Employers are already responding. Business Group on Health's 2026 survey of large employers found that 10% plan to drop weight-loss drug coverage in 2027 and 18% remain unsure. Stop-loss underwriters are watching the same numbers. A group that covers GLP-1s for weight loss carries a different aggregate risk profile than one that limits them to diabetes, and that difference shows up in renewal pricing.
Emerging Trends in Underwriting and Plan Design
Carriers are deploying more sophisticated tools to manage their books, and employers should anticipate the following:
- Increased use of data analytics and predictive modeling: Underwriters now analyze not just lagged claims but real-time pharmacy and medical data, social determinants, and even wearable device information to price risk. This can lead to sharp premium swings for groups with deteriorating risk profiles.
- Tighter exclusion of organ transplant and gene therapy: Many stop-loss contracts are carving out or sub-limiting coverage for certain ultra-high-cost procedures, pushing employers to purchase separate, specialized transplant or gene therapy stop-loss policies, an added cost.
- Advanced contracting and direct provider networks: To mitigate stop-loss costs, employers are increasingly using centers of excellence, narrow networks, and direct-to-employer platforms. When these programs demonstrably reduce claim variability, carriers may offer better terms. However, adoption requires careful coordination with stop-loss underwriters.
- Level-funded product volatility: These plans, designed for small groups, use embedded stop-loss. A single large claim can cause a group's rate to skyrocket at renewal, sometimes forcing them back to fully insured or out of coverage entirely. This segment is seeing the most dramatic rate hikes.
What Employers Can Expect in 2026 and Beyond
The trendline points to continued cost escalation into 2027. The days of flat or low-single-digit stop-loss renewals are gone. Employers should budget for specific stop-loss increases in the low to mid teens for 2027, with higher renewals for groups with poor claims experience or thin demographics. The most successful employers will adopt a proactive posture: investing in claims data transparency, improving clinical management for high-cost conditions, and working with stop-loss carriers early in the plan year rather than at renewal. Multiyear arrangements and captive insurance pools are also gaining traction as ways to dampen volatility. Stop-loss has become a strategic lever that rewards continuous attention.